Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform. It focuses on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company biotechnology segment, driven by its proprietary MITOLINE discovery engine and structure-guided virtual screening workflows, is engaged in the discovery and development of small-molecule therapeutics targeting the mitochondrial SLC25 carrier family for resistant cancers and inflammatory metabolic disease indications.